BioCardia’s (BCDA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioCardia (NASDAQ:BCDA) in a report released on Thursday morning,Benzinga reports. They currently have a $25.00 target price on the stock.

BioCardia Stock Performance

Shares of NASDAQ:BCDA opened at $1.85 on Thursday. The business has a fifty day moving average of $2.58 and a 200-day moving average of $3.30. BioCardia has a twelve month low of $1.84 and a twelve month high of $14.40. The firm has a market cap of $3.92 million, a PE ratio of -0.44 and a beta of 1.28.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.